Your institution may have access to this item. Find your institution then sign in to continue.
Title
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Authors
M. Moore; H. W. Hirte; L. Siu; A. Oza; S. J. Hotte; O. Petrenciuc; F. Cihon; C. Lathia; B. Schwartz